A small executive order from April 18, 2026 changed the conversation at this year’s NatCon. Three of the most experienced clinicians and operators in interventional psychiatry took the stage to walk through what’s actually here, what’s coming, and what patients should know before saying yes to any of it.
This isn’t fringe medicine anymore. It’s becoming standard of care, arriving in pieces.
Three things to know before you read further
- Ketamine and Spravato are already FDA-approved or off-label-available today. Psilocybin, MDMA, and ibogaine are in late-stage trials and could reach approval within the next 1–3 years.
- These drugs work differently than antidepressants. They open a temporary “critical period” in the brain where rewiring happens. The medicine is the catalyst — the therapy before and after is what makes the change stick.
- Where you get treated matters more than what you get. Reputable clinics use a three-phase model (preparation, dosing, integration). At-home injectable ketamine shipped through a telehealth-only app is, in the words of one panelist, “a bridge too far.”
Why a White House Executive Order Suddenly Made This Mainstream
On April 18, 2026, President Trump signed an executive order titled Accelerating Medical Treatments for Serious Mental Illness. Nine days later, the panel at NatCon 2026 was scrambling to update its slides.
The order did four concrete things that matter for patients:
- Directed HHS to allocate $50 million through ARPA-H to match state investments in psychedelic research
- Authorized FDA Commissioner’s National Priority Vouchers for psychedelic drugs with Breakthrough Therapy designation, cutting review timelines from 6–12 months down to 1–2
- Instructed the DEA to begin scheduling reviews in parallel with FDA review rather than after, eliminating a major post-approval delay
- Set up Right to Try pathways for investigational psychedelics, with specific mention of ibogaine
Within six days of the order, FDA Commissioner Marty Makary issued three priority vouchers — to Compass Pathways for psilocybin in treatment-resistant depression, Usona Institute for psilocybin in major depressive disorder, and Transcend Therapeutics for methylone in PTSD.
Sarah Norman, Executive Director of BrainFutures, walked the NatCon audience through one provision she felt got overlooked. The Center for Medicare and Medicaid Services Innovation Center is launching pilots for value-based payment of psychedelic care — a quiet but significant signal that even reimbursement models are being rewritten alongside the drugs.
“I don’t think got as much press, but personally, I’m very excited about [the CMMI innovation pilots] for innovative care delivery and payment structures for psychedelic medicines.” — Sarah Norman, Executive Director, BrainFutures
What Doctors Mean When They Call These “Neuroplastic” Treatments
Psychedelic medications share something the panel emphasized again and again: they don’t just change how you feel. They change how your brain learns.
Dr. Carlene MacMillan, co-founder and Chief Product Officer of Radial and a Harvard-trained child and adult psychiatrist, walked through the science. These drugs all open what neuroscientists call a “critical period” — a temporary window in which neurons can form new connections more easily.
“If you hear the phrase, ‘you can’t teach an old dog new tricks,’ I like to explain to patients: this is teaching the old dog hopefully many new healthy [habits].” — Dr. Carlene MacMillan, Co-founder & CPO, Radial
The technical term is metaplasticity — the brain’s ability not just to make new connections, but to regulate how those connections form. That regulation is exactly what makes a psychedelic different from a drug like cocaine, which floods the brain with dopamine in an unregulated way and creates the conditions for addiction.
When MacMillan explains this to patients, she reaches for a gardening metaphor.
“Set and setting matter. If you put the plant in the wrong light, [it won’t grow]. The drug is kind of like the fertilizer. And if you get all those things right, then that plant is going to thrive.” — Dr. Carlene MacMillan
“Set and setting” is a phrase patients will hear a lot. It means mindset before the session and environment during it. Both shape what the brain does with the medication.
The other thing that distinguishes these treatments: they aren’t daily pills. Lucia Huang, co-founder and CEO of Osmind — the platform behind hundreds of interventional psychiatry clinics nationwide — described the shift as moving “way far away from taking [a] daily pill and much more into this episodic pulse treatment.” Changes can begin within 24–48 hours of a dose. The deeper transformation unfolds over the weeks and months that follow, while the brain’s critical period remains open.
What’s Actually Available Now vs. What’s Coming Next
Available today
- Ketamine (off-label, IV or intramuscular in supervised clinics) for treatment-resistant depression and suicidality
- Esketamine / Spravato (FDA-approved 2019 for treatment-resistant depression; later approved for major depressive disorder with suicidal ideation)
- TMS (transcranial magnetic stimulation) — not psychedelic, but part of the same shift toward interventional psychiatry
Late-stage and on the horizon
- Psilocybin — depression, OCD, end-of-life anxiety, anorexia nervosa, smoking cessation. Compass Pathways’ COMP360 has reported two positive Phase 3 trials in treatment-resistant depression.
- MDMA — PTSD. Resilient Pharmaceuticals (formerly Lykos, formerly MAPS PBC) is moving forward after a 2024 FDA setback.
- Ibogaine — PTSD in veterans, opioid use disorder, cocaine use disorder. Promising research out of Stanford.
- LSD — generalized anxiety disorder (MindMed)
- DMT — depression
Real psychedelic therapy clinics are rarely single-modality. Patients respond differently to different treatments, and most reputable practices now offer a menu — ketamine, Spravato, TMS, and (when approved) psilocybin or MDMA — under one roof.
The Three-Phase Visit That Looks Nothing Like a Normal Therapy Appointment
Lucia Huang laid out what an actual psychedelic therapy course looks like in the clinics on her platform. Patients should expect three distinct phases.
Preparation
A therapy session before any dosing happens. The clinician helps the patient set an intention, walks through what the experience may feel like, and ensures the right mindset going in. This is the “set” in set and setting.
Dosing
The actual administration. Length varies enormously by drug:
- Ketamine / Spravato: roughly 1–2 hours
- Psilocybin: several hours
- Ibogaine: approximately 24 hours
The room itself is engineered for safety and comfort — recliner chairs, eye masks, curated music, video monitoring, and clinical staff on hand. A physician supervises overall care while mid-level providers and medical assistants handle in-room monitoring.
Integration
A therapy session after dosing, often within 24–72 hours, while the brain’s critical period is still open. This is where the actual learning happens. The medicine is the catalyst — integration is what makes the change stick.
Patients should expect to bring four things to a dosing session: a clear intention, comfortable clothes, a ride home (no driving for hours afterward), and a willingness to do the integration work afterward.
The Cautionary Tale of At-Home Ketamine
The pandemic created a regulatory loophole. The temporary suspension of the Ryan Haight Act, combined with the telehealth boom and a flood of venture capital, gave rise to a new category of company: telehealth-only providers shipping ketamine lozenges to patients who never set foot in a clinic.
In October 2023, actor Matthew Perry died from the acute effects of ketamine. The case became the public marker of a safety problem the field is still reckoning with.
MacMillan was direct on the panel about where she stands. At-home injectable ketamine right now, she said, is “a bridge too far.” She believes regulated at-home protocols may eventually be appropriate, but the field “leapfrogged a few steps” during the pandemic and has to find its way back.
Huang framed the trade-off in business terms.
“You can’t compromise safety so much just for access… you can’t go so far as to compromise safety and perhaps jeopardize the entire legitimacy [of the field].” — Lucia Huang, Co-founder & CEO, Osmind
Be skeptical of any psychedelic therapy provider who never sees you in person. Reputable Spravato programs are REMS-certified (Risk Evaluation and Mitigation Strategy) — a federal designation that requires on-site monitoring, vital signs documentation, and a 2-hour observation period after every dose.
The Insurance Reality — What Patients Are Actually Paying
This is where the system gets messy. Coverage depends heavily on which treatment, which payer, and which state.
Spravato (esketamine) has dedicated billing codes. The two main HCPCS codes are G2082 (administration with up to 56 mg) and G2083 (administration with more than 56 mg). Both bundle the medication, the administration, and the required clinical observation period. Commercial insurance and Medicare typically reimburse. Medicaid coverage varies by state. Most plans require prior authorization with documentation of 2–4 failed antidepressant trials.
Ketamine (off-label) is largely cash-pay. Some clinics bill evaluation-and-management codes alongside infusion codes, but commercial coverage is inconsistent.
Psilocybin and MDMA therapy services already have temporary CPT codes built in anticipation of approval. In June 2023, the AMA CPT Editorial Panel established Category III codes 0820T, 0821T, and 0822T for “Continuous In-Person Monitoring and Intervention During Psychedelic Medication Therapy.” These are placeholders — they’ll need to convert to permanent Category I codes to be widely reimbursable.
MacMillan’s view from the panel: traditional fee-for-service is a poor fit for treatments requiring 6–24 hours of clinical time. She expects value-based payment models to emerge as the dominant approach — and the CMMI innovation pilots in the executive order are the first concrete signal that’s already happening.
How to Find a Reputable Psychedelic Therapy Practice
A short checklist before you book:
- Look for established interventional psychiatry networks. Multi-modal practices (ketamine, Spravato, TMS, and psychedelic therapy when approved) are generally further along the safety and infrastructure curve than single-modality startups.
- Verify REMS certification for any Spravato program. This is non-negotiable for that drug.
- Ask about the three-phase model. If a clinic offers the dosing piece without preparation and integration, that’s a red flag.
- Confirm in-person care. A telehealth-only ketamine prescription mailed to your house is not the same as a supervised clinical experience.
- Ask about prior authorization help. Reputable practices have staff who specialize in the 2–4 antidepressant-trial documentation that most payers require.
For patients who have cycled through multiple SSRIs without relief — and that, by some estimates from the landmark STARD trial, is roughly two-thirds of people who try them — psychedelic medicine isn’t fringe anymore. The federal tailwind is here. The science is here. The infrastructure is being built clinic by clinic. And in 2026, the question is no longer whether this category of treatment will reach patients, but how quickly and how safely it gets there.
